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Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral disorder of childhood; one of the most prevalent chronic health conditions 
affecting school-aged children and also the most extensively 
studied mental disorder of childhood [1]. It represents a complex 
problem because it appears at an early age, affects the daily lives 
of children from all areas of development, and is likely to persist 
throughout life [2]. Although the symptoms of ADHD begin in 
childhood, it can continue through adolescence and adulthood. 
Even though hyperactivity tends to improve as the child becomes 
an adolescent, problem with inattention, disorganization, and 
poor impulse control often continues through the adolescent 
years and into adulthood. Current understanding is that ADHD 
may be caused by interactions between genes and environmental 
factors. The non-genetic factors that may contribute to ADHD are 
(i) cigarette smoking, alcohol use, or drug use during pregnancy, 
(ii) exposure to environmental toxins, such as high levels of lead, 
at a young age, (iii) low birth weight, and (iv) brain injuries [3].
Although there is no global consensus, meta-regression analyses 
have estimated the worldwide ADHD prevalence to be between 
5.3% and 7.1% in children and adolescents and at 3.4% in adults [4]. 
Evidence suggests that the prevalence of ADHD is greater in males 
than females. Gender ratios varied by country ranging from 1:3 to 
1:16 in females:males [5]. The American Psychiatric Association 
identifies three core symptoms that characterize ADHD: Inattention, 
hyperactivity, and impulsivity. According to DSM V, six or more 
of the symptoms of inattention or hyperactivity/impulsivity should 
have persisted for at least 6 months to a degree that is maladaptive 
and inconsistent with development level to fulfill the diagnosis of 
ADHD. For children aged more than 17 years, only five criteria 
are necessary. Other criteria that have to be fulfilled include onset 
of symptoms before 12 years of age, presence in two or more 
settings, and clear evidence of significant impairment in social, 
academic, or occupational functioning. The symptoms should not 
occur exclusively during the course of a pervasive developmental 
disorder, schizophrenia, or other psychotic disorder and are not 
better accounted for by another mental disorder [6].
BIOPSYCHOSOCIAL APPROACH
The biopsychosocial model of health and illness is a framework 
developed by Dr. George L. Engel in 1977 that states that 
interactions between biological, psychological, and social factors 
determine the cause, manifestation, and outcome of wellness and 
disease [7]. The biopsychosocial model argues that any one factor 
is not sufficient and that it is the interplay between people’s genetic 
makeup (biology), mental health and behavior (psychology), and 
cultural (social) context that determines the course of their health-
related outcomes. It emphasizes the importance of understanding 
human health in a holistic context [8]. This approach can be 
used in explaining the symptoms and also targeting these 
symptoms in the management. It has been primarily used within 
clinical settings to address various psychological disorders 
including depression and anxiety as well as medical ailments, 
including cancer and pain [9]. The International Classification of 
Functioning, Disability, and Health: Children and Youth Version, 
endorsed by the World Health Organization (2007), is based on the 
biopsychosocial model that emphasizes how the child/adolescent 
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functions as a complex interaction between the individual factors 
and contextual factors of the environment [10].
ADHD, as a clinical and behavioral entity, may be considered 
likely to be approached from the biopsychosocial approach, 
since it is recognized that the basic neurobiological disorder is 
equally determined and influenced by other multiple external and 
environmental factors that can lead to important implications in 
daily, functional, and social activities and exacerbate the clinical 
manifestations and comorbidities in different contexts [11].
BIOLOGICAL ASPECT
ADHD is a neurobiological disorder of the prefrontal cortex and 
its connections. Many symptoms in ADHD-afflicted persons are 
comparable with symptoms from patients suffering from frontal 
lobe damage, which highlights the importance of the frontal 
cortical networks [12]. Prefrontal cortex determines executive 
functions of the brain which include the ability to (i) inhibit 
inappropriate behaviors and thoughts, (ii) regulate our attention, 
(iii) monitor our actions, and (iv) plan and organize for the 
future. Circuits within the prefrontal cortex relevant to ADHD 
include dorsal front-striatal, orbito-fronto-striatal, and fronto-
cerebellar circuits [13]. Optimal levels of dopamine acting at 
D1 receptors and norepinephrine acting at postsynaptic alpha 
2A-adrenoceptors are essential to prefrontal cortex function. Low 
levels of these neurotransmitters and abnormal activation of the 
fronto-striato-cerebellar circuits are seen in children with ADHD. 
Genetic factors such as mutations in DAT1 gene and DRD4 
gene have been implicated for abnormalities in the function of 
neurotransmitter receptors [14].
Pharmacotherapy in ADHD is directed to the correction of 
the above defects in neurotransmitter regulation and circuitry. 
Stimulants such as methylphenidate and amphetamine group 
drugs target the dopamine transporter (DAT) and the noradrenaline 
transporter in presynaptic neuron, thereby inhibiting dopamine 
and noradrenaline reuptake into presynaptic neuron. Hence, there 
is increased dopamine and noradrenaline levels in the synaptic 
cleft for action in the prefrontal cortex.
Stimulants also cause direct stimulation of alpha2 and D1 
receptors in postsynaptic neuron. In addition, amphetamine 
promotes the release of catecholamines from vesicles into the 
cytosol and from the cytosol into the synaptic cleft, thereby 
directly increasing their concentration in the synaptic cleft. 
Methylphenidate is the most widely used and recommended 
drug among the stimulants. Start with low dose and go slow in 
increasing the dose are the rules in stimulants. Start at 5-10mg/day 
and slowly increases every 5–7 days until optimal results are 
achieved or side effects appear [15]. Delayed release preparations 
have the advantage of less frequent dosing, more compliance, and 
less abuse potential but are more costly. Adverse effects include 
reduced appetite, abdominal discomfort, headache, irritability, 
sleep problems, and tachycardia. Small reduction in height 
velocity is an uncommon but significant concern, and hence, 
height and weight must be monitored at least semi-annually. If 
the height drops across two major centiles, stop the drug and 
treatment with a non-stimulant is to be instituted. Amphetamine 
group of drugs is presently not available in India for the treatment 
of ADHD because of abuse potential.
Another commonly used medication is atomoxetine - a 
selective noradrenaline reuptake inhibitor. It targets the 
norepinephrine transporter and increases extracellular levels of 
dopamine and noradrenaline in the prefrontal cortex because 
norepinephrine transporter in prefrontal cortex also causes 
reuptake of dopamine. However, in contrast to MPH, it does not 
increase dopamine levels in striatum or nucleus accumbens, so 
there are no drug abuse liabilities [16]. In comparative studies, the 
efficacy of atomoxetine is found to be non-inferior to immediate-
release methylphenidate but significantly less effective than the 
extended-release preparation. It is started at a dose of 0.5 mg/kg 
per day and later increased up to 1.2 mg/kg. The advantage of 
atomoxetine over stimulants includes lack of abuse risk and 
usefulness in comorbid anxiety or tic disorders. Adverse effects 
include somnolence, gastrointestinal upset/nausea, and reduced 
appetite and weight loss [17].
Alpha 2 agonists are third-line drugs used in the treatment of 
ADHD. They cause direct stimulation of α2-adrenergic receptors 
leading to improve the efficiency of synaptic transmission in 
prefrontal cortex through the reduction of camp production. 
They are indicated, if the patient fails to respond to trials of two 
different stimulants, has intolerable side effects, or fails to respond 
to a trial of atomoxetine. They can also be used as an add-on to 
stimulants in patients with tic disorders. The main drugs in this 
group include clonidine and guanfacine. Guanfacine is a selective 
alpha-2a agonist and has the advantage of less sedation [18]. 
Other drugs that may be used in ADHD included antidepressants 
such as bupropion, venlafaxine, tricyclic antidepressants, and 
modafinil.
PSYCHOLOGICAL ASPECT
Psychological component of the biopsychosocial model seeks to 
find a psychological foundation for a particular array of symptoms 
and target them in treatment. Various neuropsychological 
theories have highlighted the behavior mechanisms reinforcing 
the symptoms of ADHD [19]. The dysfunctioning dopaminergic 
prefrontal connections lead to executive deficits and altered 
reinforcement and extinction processes, characteristic of ADHD. 
These include (i) problems in working memory, (ii) defective 
response inhibition (i.e., suppression of actions that are 
inappropriate in a given context and that interfere with goal-
driven behavior), (iii) delay aversion (i.e., the tendency to choose 
a smaller immediate reward rather than wait for a large delayed 
reward), and (iv) deficient operant extinction. These deficits are 
targeted in behavior therapy. Most behavioral therapy programs for 
children with ADHD consider immediate positive reinforcement 
for good behavior (in the form of praise or social rewards) as an 
important component. In addition, caregivers of ADHD children 
should prevent the development of unwanted behavior, because 
the extinction deficit makes it difficult to reverse such behavior, 
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once established. Hence, the second key element is to make 
consequences for bad behavior (negative reinforcement) clear, 
understandable, and consistent. Furthermore, minor attention-
seeking inappropriate behaviors have to be ignored [20].
In adolescents with ADHD, cognitive behavior therapy can be 
applied for helping them develop a more planned and reflective 
way of thinking and behaving. It helps them to systematically 
work on their deficit areas and to adopt a more, systematic, 
and goal-directed approach to tasks and problem-solving. For 
example, children are encouraged to adopt a four-point scheme 
when faced with a problem or task: (i) What is the problem? 
(ii) What is my plan? (iii) Do I use my plan? And (iv) How did I 
do? It helps them to evaluate and monitor their own progress [21].
SOCIAL ASPECT
Social implications in ADHD are multidimensional. Disruptive 
social environments can predispose to the development of 
ADHD, and at the same time, ADHD itself can have manifold 
effects on the individual child and family. Parental ADHD is 
associated with disruptive family environment, suboptimal 
parenting practices, and negative emotional family environments, 
which predispose unfavorable behavioral development in an 
ADHD child and increase the risk of later oppositional defiant 
disorder and conduct disorder [22], particularly in boys. Other 
factors which increase risk include parental substance abuse or 
criminality, poor monitoring and supervision of children, low 
parental involvement, authoritarian child-rearing attitudes, harsh, 
lax or inconsistent discipline, and history of violent victimization. 
Research indicates that the presence of ADHD in a child is 
associated with disturbances in family and marital functioning, 
disrupted parent-child relationships, reduced parenting self-
efficacy, and increased levels of parental stress [23]. Hence, 
parent education, family education, and family therapy play an 
important role in the management of ADHD.
ADHD in a child is associated with greater risks for low 
academic achievement, poor school performance, retention in 
grade, school suspensions, and expulsions. Schools often force 
children to conform to a narrow, predefined standard of child 
development and behavior. As children with ADHD, due to their 
inherent deficits in executive functions, find it difficult to conform 
to a socially constructed norm, they are considered maladaptive 
and suffer social rejection by peers which further lowers their 
self-esteem.
Children with ADHD may require changes in their educational 
program, including (a) provision of tutoring or resource room 
support (either in a one-on-one setting or within the classroom), (b) 
classroom modifications, (c) accommodations, and (d) behavioral 
interventions. The problem is that optimal contingencies only 
exist during the training session or under certain circumstances, 
and outside these, inconsistent and unpredictable contingencies 
are the rule. The school may, however, help an ADHD child 
to adjust to the school requirements by creating an optimal 
learning environment [24]. Classroom behavior management 
is an important aspect of ADHD management in school-going 
children. It can be given by mainstream teachers with appropriate 
training. Various strategies that can be used include (i) verbal 
reinforcement of good behavior, (ii) selectively ignore minor 
inappropriate attention-seeking behavior, (iii) remove nuisance/
distraction items, (iv) allow for “escape valve” outlets, (v) hurdle 
helping shadow teacher, (vi) peer mediation - study buddy, 
and (vii) proximity control - seat near the teacher. Academic 
difficulties can be helped by making assignments clear and not 
long and repetitive. Teachers have to be sensitive to self-esteem 
issues in the student [25,26].
Approximately 50% of ADHD children have significant 
problems in social relationships with other children because 
of impulsivity, poor listening skills, and aggressiveness [27]. 
Options include (i) social skill classes with role play which model 
different solutions to common social problems, (ii) problem-
solving sessions with discussions with a small group of students 
where the conflict arise, and (iii) talking to each other in a 
supervised setting to resolve their problems.
CONCLUSION
It is important to understand that biological, psychological, and 
social factors play equally important roles in the pathogenesis 
and the manifestations of ADHD. Therefore, the management of 
child with ADHD should include components addressing all these 
areas, as appropriate for the age. Pharmacotherapy by a clinician 
will help in reducing the symptoms of ADHD, but behavior 
impairments and academic difficulties require behavior and family 
therapy and educational assistance from teachers. Similarly, vice 
versa, behavior therapy alone is inferior to pharmacotherapy 
combined with behavior therapy. Hence, the various modalities 
of treatment should not be considered mutually exclusive, but a 
right combination of them will help in ultimately improving the 
quality of life of the child and the family.
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